Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females

A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01301456

Enrollment

Registered

2011-02-23

Start date

2011-03-31

Completion date

2012-04-30

Last updated

2018-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, Glucose Metabolism Disorders, Metabolic Diseases

Keywords

Phase 1, Type 2 Diabetes, CVX-096

Brief summary

The primary objective of this study is to evaluate the safety and tolerability of PF-04856883 (CVX-096) in adult female subjects with Type 2 diabetes mellitus on high dose of metformin.

Interventions

BIOLOGICALPlacebo

Single subcutaneous injection of placebo

BIOLOGICALPF-04856883

Single subcutaneous injection of PF-04856883

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* History of Type 2 diabetes and currently being treated with high dose metformin * BMI between 22.0 and 40.0 kg/m2 * HbA1c between 7.0-10.0% * Fasting C-peptide \>1.21 ng/mL

Exclusion criteria

* History of clinically significant chronic conditions other than Type 2 diabetes not well controlled by either diet or medications * Treatment with anti-diabetic therapies other than metformin * History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody * Males or women of childbearing potential

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose (Day 50) that were absent before treatment or that worsened relative to pretreatment state.
Number of Participants With Clinically Significant Physical Examination Findings	Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50	Physical examination included examination of general appearance, head, ears, eyes (including fundoscopy), nose, mouth, throat, neck (including thyroid), skin, breast (optional), cardiac, respiratory, gastrointestinal, musculoskeletal and neurological systems.
Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50	ECG parameters included pulse rate (PR) interval, QRS interval, corrected QT interval using Bazett's formula (QTcB) and corrected QT interval using Fridericia's formula (QTcF). ECG criteria of clinically significant concern were 1) PR interval: greater than equal to (\>=) 25 percent (%) increase when baseline greater than (\>)200 milliseconds (msec); or increase \>=50% when baseline less than or equal to (\<=200) msec; 2) QRS interval: \>=25% increase when baseline \>100 msec; \>=50% increase when baseline \<= 100 msec; 3) QTCF interval: QTc interval using Fridericia's formula (QTcF interval) and Bazett's formula (QTcB interval): absolute value 450 - \<480 msec, 480 - \<500 msec \>=500; absolute change 30 - \<60, \>=60 msec. The number of participants with potentially clinically significant ECG findings at any visit were reported. IFB = increase from baseline.
Number of Participants With Vital Sign Abnormalities	Stage 1: Baseline up to Day 29; Stage 2 : Baseline up to Day 50	Criteria for vital signs abnormalities: sitting/supine systolic pulse rate less than (\<) 40 beats per minute (bpm) or greater than (\>) 120 bpm, standing/supine systolic pulse \< 40 bpm or \> 140 bpm, systolic blood pressure of \>=30 millimeters of mercury (mmHg) change from baseline and systolic blood pressure \<90 mmHg, diastolic blood pressure \>=20 mmHg change from baseline and diastolic blood pressure \<50 mm Hg.
Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements	Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50	Following parameters were analyzed for laboratory examination: Hematology: hemoglobin, hematocrit, red blood cell (RBC) \<0.8\lower limit of the reference range (LLRR); leukocytes \<0.6\LLRR or \>1.5\ULRR; platelet count \<0.5\LLRR or \>1.75\upper limit of the reference range (ULRR); total neutrophils (absolute \[abs\]), lymphocytes (abs) \<0.8\LLRR or \>1.2\ULRR; eosinophils (abs), basophils (abs), monocytes (abs) \>1.2\ULRR; chemistry (total bilirubin, direct bilirubin, indirect bilirubin \>1.5\ULRR; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3\ULRR, albumin, total protein \<0.8\LLRR or \>1.2\ULRR; blood urea nitrogen (BUN), creatinine \>1.3\ULRR; glucose (fasting) \<0.6\LLRR or \>1.5\ULRR; uric acid \>1.2\ ULRR; sodium \<0.95\LLRR or \>1.05\ULRR; potassium, chloride, bicarbonate, calcium \<0.9\LLRR or \>1.1\ULRR. Urinalysis: Urine white blood cell (WBC), Urine RBC =\>20/ high-power field (HPF).

Secondary

Measure	Time frame	Description
Area Under the Concentration Time Curve From Time Zero to Time Tau (AUCtau) of PF-04856883: Stage 2	predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168 hours postdose Day 1; predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168 hours postdose Day 22	Area under the serum concentration-time curve from time 0 to tau (AUCtau), where tau was the dosing interval of 168 hours.
Apparent Clearance (CL/F) of PF-04856883: Stage 1	predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1	It was calculated by dividing dose with AUC (0 - ∞) where AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). Outcome measure was planned to be analyzed in Stage 1 only.
Apparent Clearance (CL/F) of PF-04856883: Stage 2	predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22	It was calculated by dividing dose with AUC (0 - ∞) where AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). Outcome measure was planned to be analyzed in Stage 2 only. Data was not estimable if values were below the limit of quantification.
Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 1	predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1	—
Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 2	predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22	—
Terminal Elimination Half- Life (t1/2) of PF-04856883: Stage 1	predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1	—
Terminal Elimination Half-life (t1/2) of PF-04856883: Stage 2	predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22	—
Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline, Day 3 and 8	Change from baseline in post-prandial area under the plasma glucose concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC
Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline, Day 3, 15, 24, 29 and 50	Change from baseline in post-prandial area under the plasma glucose concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.
Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline, Day 3 and 8	Change from baseline in post-prandial plasma insulin AUC under the plasma insulin concentration versus time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.
Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline, Day 3, 15, 24, 29 and 50	Change from baseline in post-prandial plasma insulin AUC under the plasma insulin concentration versus time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.
Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 1	predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1	—
Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline, Day 3, 15, 24, 29 and 50	Change from baseline in post-prandial area under the plasma C-peptide concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.
Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Baseline, Day 2, 4, 6, 15, 22 and 29	—
Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Baseline, Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43	—
Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2	Baseline, Day 30	A normalized area under the curve (NAUC) were computed by dividing the AUC by the amount of time between the last time point captured and the first time point captured.
Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2	Baseline, Day 29 and 50	HbA1c is a measure of the glycosylated hemoglobin. Change (measured as percent): HbA1c at observation minus HbA1c at baseline. Outcome measure was planned to analyzed only for Stage 2.
Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Baseline, Day 8, 15 and 29	—
Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Baseline, Day 8, 15, 22, 29 and 50	—
Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Baseline, Day 8, 15 and 29	—
Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Baseline, Day 8, 15, 22, 29 and 50	—
Number of Participants With Anti-Drug Antibodies (ADA): Stage 1	Day 1 and 29	—
Number of Participant With Anti-Drug Antibodies (ADA): Stage 2	Day 1, 29 and 50	—
Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline, Day 3 and 8	Change from baseline in post-prandial area under the plasma C-peptide concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.
Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 2	predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336 hours postdose on Day 1; predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22	—
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 1	predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1	—
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 2	predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336 hours postdose on Day 1; predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22	—
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) of PF-04856883: Stage 1	predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1	AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Countries

United States

Participant flow

Pre-assignment details

Data for reporting arm Placebo 1a and 1b in stage 1 was planned to be pooled during analysis, as per protocol. Study consisted of two stages: stage 1 and stage 2. Participants were enrolled and randomized for stage 1 and stage 2 separately.

Participants by arm

Arm	Count
Stage 1: PF-04856883 Placebo Participants received placebo matched to PF-04856883 subcutaneously injection once on Day 1 in Stage 1.	15
Stage 1: PF-04856883 4 mg Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.	5
Stage 1: PF-04856883 8 mg Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.	6
Stage 1: PF-04856883 12 mg Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.	6
Stage 1: PF-04856883 18 mg Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.	7
Stage 1: PF-04856883 24 mg Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.	5
Stage 1: PF-04856883 36 mg Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.	8
Stage 2: Placebo Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.	7
Stage 2: PF-04856883 12 mg Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.	5
Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.	7
Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.	7
Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.	6
Total	84

Withdrawals & dropouts

Period	Reason	FG002	FG004	FG006	FG010
Stage 1	Randomized but not treated	0	0	1	0
Stage 1	Withdrawal by Subject	1	1	0	0
Stage 2	Adverse Event	0	0	0	1

Baseline characteristics

Characteristic	Total	Stage 1: PF-04856883 4 mg	Stage 1: PF-04856883 8 mg	Stage 1: PF-04856883 12 mg	Stage 1: PF-04856883 18 mg	Stage 1: PF-04856883 24 mg	Stage 1: PF-04856883 36 mg	Stage 2: Placebo	Stage 2: PF-04856883 12 mg	Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg	Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg	Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg	Stage 1: PF-04856883 Placebo
Age, Customized <18 years	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants
Age, Customized >=65 years	13 participants	2 participants	1 participants	2 participants	1 participants	1 participants	2 participants	1 participants	0 participants	3 participants	0 participants	0 participants	0 participants
Age, Customized Between 18 and 64 years	71 participants	3 participants	5 participants	4 participants	6 participants	4 participants	6 participants	6 participants	5 participants	4 participants	7 participants	6 participants	15 participants
Sex: Female, Male Female	84 Participants	5 Participants	6 Participants	6 Participants	7 Participants	5 Participants	8 Participants	7 Participants	5 Participants	7 Participants	7 Participants	6 Participants	15 Participants
Sex: Female, Male Male	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk	EG008 affected / at risk	EG009 affected / at risk	EG010 affected / at risk	EG011 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —
other Total, other adverse events	8 / 15	1 / 5	0 / 6	2 / 6	4 / 7	3 / 5	4 / 7	4 / 7	5 / 5	5 / 7	5 / 7	5 / 6
serious Total, serious adverse events	0 / 15	0 / 5	0 / 6	0 / 6	0 / 7	0 / 5	0 / 7	0 / 7	0 / 5	0 / 7	0 / 7	0 / 6

Outcome results

Primary

Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements

Following parameters were analyzed for laboratory examination: Hematology: hemoglobin, hematocrit, red blood cell (RBC) \<0.8\*lower limit of the reference range (LLRR); leukocytes \<0.6\*LLRR or \>1.5\*ULRR; platelet count \<0.5\*LLRR or \>1.75\*upper limit of the reference range (ULRR); total neutrophils (absolute \[abs\]), lymphocytes (abs) \<0.8\*LLRR or \>1.2\*ULRR; eosinophils (abs), basophils (abs), monocytes (abs) \>1.2\*ULRR; chemistry (total bilirubin, direct bilirubin, indirect bilirubin \>1.5\*ULRR; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3\*ULRR, albumin, total protein \<0.8\*LLRR or \>1.2\*ULRR; blood urea nitrogen (BUN), creatinine \>1.3\*ULRR; glucose (fasting) \<0.6\*LLRR or \>1.5\*ULRR; uric acid \>1.2\* ULRR; sodium \<0.95\*LLRR or \>1.05\*ULRR; potassium, chloride, bicarbonate, calcium \<0.9\*LLRR or \>1.1\*ULRR. Urinalysis: Urine white blood cell (WBC), Urine RBC =\>20/ high-power field (HPF).

Time frame: Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50

Population: The safety population included all randomized participants who received at least 1 dose of study treatment.

Arm	Measure	Value (NUMBER)
Stage 1: PF-04856883 Placebo	Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements	15 participants
Stage 1: PF-04856883 4 mg	Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements	5 participants
Stage 1: PF-04856883 8 mg	Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements	6 participants
Stage 1: PF-04856883 12 mg	Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements	6 participants
Stage 1: PF-04856883 18 mg	Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements	7 participants
Stage 1: PF-04856883 24 mg	Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements	4 participants
Stage 1: PF-04856883 36 mg	Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements	6 participants
Stage 2: Placebo	Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements	7 participants
Stage 2: PF-04856883 12 mg	Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements	5 participants
Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg	Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements	7 participants
Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg	Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements	7 participants
Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg	Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements	6 participants

Primary

Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)

ECG parameters included pulse rate (PR) interval, QRS interval, corrected QT interval using Bazett's formula (QTcB) and corrected QT interval using Fridericia's formula (QTcF). ECG criteria of clinically significant concern were 1) PR interval: greater than equal to (\>=) 25 percent (%) increase when baseline greater than (\>)200 milliseconds (msec); or increase \>=50% when baseline less than or equal to (\<=200) msec; 2) QRS interval: \>=25% increase when baseline \>100 msec; \>=50% increase when baseline \<= 100 msec; 3) QTCF interval: QTc interval using Fridericia's formula (QTcF interval) and Bazett's formula (QTcB interval): absolute value 450 - \<480 msec, 480 - \<500 msec \>=500; absolute change 30 - \<60, \>=60 msec. The number of participants with potentially clinically significant ECG findings at any visit were reported. IFB = increase from baseline.

Time frame: Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50

Population: The safety population included all randomized participants who received at least 1 dose of study treatment.

Arm	Measure	Group	Value (NUMBER)
Stage 1: PF-04856883 Placebo	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcB Interval IFB: 30-<60 msec	0 participants
Stage 1: PF-04856883 Placebo	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum PR Interval IFB: >=25 or 50%	0 participants
Stage 1: PF-04856883 Placebo	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcF Interval IFB: 30-<60 msec	0 participants
Stage 1: PF-04856883 4 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcF Interval IFB: 30-<60 msec	0 participants
Stage 1: PF-04856883 4 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcB Interval IFB: 30-<60 msec	0 participants
Stage 1: PF-04856883 4 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum PR Interval IFB: >=25 or 50%	0 participants
Stage 1: PF-04856883 8 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcF Interval IFB: 30-<60 msec	0 participants
Stage 1: PF-04856883 8 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum PR Interval IFB: >=25 or 50%	0 participants
Stage 1: PF-04856883 8 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcB Interval IFB: 30-<60 msec	0 participants
Stage 1: PF-04856883 12 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcB Interval IFB: 30-<60 msec	0 participants
Stage 1: PF-04856883 12 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcF Interval IFB: 30-<60 msec	0 participants
Stage 1: PF-04856883 12 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum PR Interval IFB: >=25 or 50%	0 participants
Stage 1: PF-04856883 18 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcB Interval IFB: 30-<60 msec	0 participants
Stage 1: PF-04856883 18 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum PR Interval IFB: >=25 or 50%	0 participants
Stage 1: PF-04856883 18 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcF Interval IFB: 30-<60 msec	0 participants
Stage 1: PF-04856883 24 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum PR Interval IFB: >=25 or 50%	0 participants
Stage 1: PF-04856883 24 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcF Interval IFB: 30-<60 msec	1 participants
Stage 1: PF-04856883 24 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcB Interval IFB: 30-<60 msec	1 participants
Stage 1: PF-04856883 36 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum PR Interval IFB: >=25 or 50%	0 participants
Stage 1: PF-04856883 36 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcB Interval IFB: 30-<60 msec	1 participants
Stage 1: PF-04856883 36 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcF Interval IFB: 30-<60 msec	0 participants
Stage 2: Placebo	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum PR Interval IFB: >=25 or 50%	1 participants
Stage 2: Placebo	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcB Interval IFB: 30-<60 msec	0 participants
Stage 2: Placebo	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcF Interval IFB: 30-<60 msec	0 participants
Stage 2: PF-04856883 12 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum PR Interval IFB: >=25 or 50%	0 participants
Stage 2: PF-04856883 12 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcB Interval IFB: 30-<60 msec	1 participants
Stage 2: PF-04856883 12 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcF Interval IFB: 30-<60 msec	1 participants
Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcF Interval IFB: 30-<60 msec	0 participants
Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcB Interval IFB: 30-<60 msec	0 participants
Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum PR Interval IFB: >=25 or 50%	0 participants
Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum PR Interval IFB: >=25 or 50%	1 participants
Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcF Interval IFB: 30-<60 msec	0 participants
Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcB Interval IFB: 30-<60 msec	0 participants
Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcF Interval IFB: 30-<60 msec	0 participants
Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum PR Interval IFB: >=25 or 50%	0 participants
Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg	Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	Maximum QTcB Interval IFB: 30-<60 msec	1 participants

Primary

Number of Participants With Clinically Significant Physical Examination Findings

Physical examination included examination of general appearance, head, ears, eyes (including fundoscopy), nose, mouth, throat, neck (including thyroid), skin, breast (optional), cardiac, respiratory, gastrointestinal, musculoskeletal and neurological systems.

Time frame: Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50

Population: The safety population included all randomized participants who received at least 1 dose of study treatment.

Arm	Measure	Value (NUMBER)
Stage 1: PF-04856883 Placebo	Number of Participants With Clinically Significant Physical Examination Findings	0 participants
Stage 1: PF-04856883 4 mg	Number of Participants With Clinically Significant Physical Examination Findings	0 participants
Stage 1: PF-04856883 8 mg	Number of Participants With Clinically Significant Physical Examination Findings	0 participants
Stage 1: PF-04856883 12 mg	Number of Participants With Clinically Significant Physical Examination Findings	0 participants
Stage 1: PF-04856883 18 mg	Number of Participants With Clinically Significant Physical Examination Findings	0 participants
Stage 1: PF-04856883 24 mg	Number of Participants With Clinically Significant Physical Examination Findings	0 participants
Stage 1: PF-04856883 36 mg	Number of Participants With Clinically Significant Physical Examination Findings	0 participants
Stage 2: Placebo	Number of Participants With Clinically Significant Physical Examination Findings	0 participants
Stage 2: PF-04856883 12 mg	Number of Participants With Clinically Significant Physical Examination Findings	0 participants
Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg	Number of Participants With Clinically Significant Physical Examination Findings	0 participants
Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg	Number of Participants With Clinically Significant Physical Examination Findings	0 participants
Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg	Number of Participants With Clinically Significant Physical Examination Findings	0 participants

Primary

Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose (Day 50) that were absent before treatment or that worsened relative to pretreatment state.

Time frame: Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50

Population: The safety population included all randomized participants who received at least 1 dose of study treatment.

Arm	Measure	Group	Value (NUMBER)
Stage 1: PF-04856883 Placebo	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	SAE	0 participants
Stage 1: PF-04856883 Placebo	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	AE	8 participants
Stage 1: PF-04856883 4 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	AE	1 participants
Stage 1: PF-04856883 4 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	SAE	0 participants
Stage 1: PF-04856883 8 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	AE	0 participants
Stage 1: PF-04856883 8 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	SAE	0 participants
Stage 1: PF-04856883 12 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	SAE	0 participants
Stage 1: PF-04856883 12 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	AE	2 participants
Stage 1: PF-04856883 18 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	SAE	0 participants
Stage 1: PF-04856883 18 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	AE	4 participants
Stage 1: PF-04856883 24 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	SAE	0 participants
Stage 1: PF-04856883 24 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	AE	3 participants
Stage 1: PF-04856883 36 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	SAE	0 participants
Stage 1: PF-04856883 36 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	AE	4 participants
Stage 2: Placebo	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	AE	4 participants
Stage 2: Placebo	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	SAE	0 participants
Stage 2: PF-04856883 12 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	AE	5 participants
Stage 2: PF-04856883 12 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	SAE	0 participants
Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	SAE	0 participants
Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	AE	5 participants
Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	SAE	0 participants
Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	AE	5 participants
Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	SAE	0 participants
Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	AE	5 participants

Primary

Number of Participants With Vital Sign Abnormalities

Criteria for vital signs abnormalities: sitting/supine systolic pulse rate less than (\<) 40 beats per minute (bpm) or greater than (\>) 120 bpm, standing/supine systolic pulse \< 40 bpm or \> 140 bpm, systolic blood pressure of \>=30 millimeters of mercury (mmHg) change from baseline and systolic blood pressure \<90 mmHg, diastolic blood pressure \>=20 mmHg change from baseline and diastolic blood pressure \<50 mm Hg.

Time frame: Stage 1: Baseline up to Day 29; Stage 2 : Baseline up to Day 50

Population: The safety population included all randomized participants who received at least 1 dose of study treatment.

Arm	Measure	Value (NUMBER)
Stage 1: PF-04856883 Placebo	Number of Participants With Vital Sign Abnormalities	15 participants
Stage 1: PF-04856883 4 mg	Number of Participants With Vital Sign Abnormalities	5 participants
Stage 1: PF-04856883 8 mg	Number of Participants With Vital Sign Abnormalities	6 participants
Stage 1: PF-04856883 12 mg	Number of Participants With Vital Sign Abnormalities	6 participants
Stage 1: PF-04856883 18 mg	Number of Participants With Vital Sign Abnormalities	7 participants
Stage 1: PF-04856883 24 mg	Number of Participants With Vital Sign Abnormalities	5 participants
Stage 1: PF-04856883 36 mg	Number of Participants With Vital Sign Abnormalities	7 participants
Stage 2: Placebo	Number of Participants With Vital Sign Abnormalities	7 participants
Stage 2: PF-04856883 12 mg	Number of Participants With Vital Sign Abnormalities	5 participants
Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg	Number of Participants With Vital Sign Abnormalities	7 participants
Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg	Number of Participants With Vital Sign Abnormalities	7 participants
Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg	Number of Participants With Vital Sign Abnormalities	6 participants

Secondary

Apparent Clearance (CL/F) of PF-04856883: Stage 1

It was calculated by dividing dose with AUC (0 - ∞) where AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). Outcome measure was planned to be analyzed in Stage 1 only.

Time frame: predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1

Population: PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Apparent Clearance (CL/F) of PF-04856883: Stage 1	89.14 milliliter per hour (mL/hr)	Geometric Coefficient of Variation 84
Stage 1: PF-04856883 4 mg	Apparent Clearance (CL/F) of PF-04856883: Stage 1	84.08 milliliter per hour (mL/hr)	Geometric Coefficient of Variation 59
Stage 1: PF-04856883 8 mg	Apparent Clearance (CL/F) of PF-04856883: Stage 1	40.60 milliliter per hour (mL/hr)	Geometric Coefficient of Variation 68
Stage 1: PF-04856883 12 mg	Apparent Clearance (CL/F) of PF-04856883: Stage 1	34.13 milliliter per hour (mL/hr)	Geometric Coefficient of Variation 35
Stage 1: PF-04856883 18 mg	Apparent Clearance (CL/F) of PF-04856883: Stage 1	33.73 milliliter per hour (mL/hr)	Geometric Coefficient of Variation 14
Stage 1: PF-04856883 24 mg	Apparent Clearance (CL/F) of PF-04856883: Stage 1	55.32 milliliter per hour (mL/hr)	Geometric Coefficient of Variation 42

Secondary

Apparent Clearance (CL/F) of PF-04856883: Stage 2

Time frame: predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Apparent Clearance (CL/F) of PF-04856883: Stage 2	44.67 mL/hr	Geometric Coefficient of Variation 28
Stage 1: PF-04856883 4 mg	Apparent Clearance (CL/F) of PF-04856883: Stage 2	NA mL/hr	—
Stage 1: PF-04856883 8 mg	Apparent Clearance (CL/F) of PF-04856883: Stage 2	NA mL/hr	—
Stage 1: PF-04856883 12 mg	Apparent Clearance (CL/F) of PF-04856883: Stage 2	NA mL/hr	—

Secondary

Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 1

Time frame: predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 1	18760 milliliter (mL)	Geometric Coefficient of Variation 90
Stage 1: PF-04856883 4 mg	Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 1	21710 milliliter (mL)	Geometric Coefficient of Variation 59
Stage 1: PF-04856883 8 mg	Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 1	9191 milliliter (mL)	Geometric Coefficient of Variation 51
Stage 1: PF-04856883 12 mg	Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 1	7127 milliliter (mL)	Geometric Coefficient of Variation 40
Stage 1: PF-04856883 18 mg	Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 1	8437 milliliter (mL)	Geometric Coefficient of Variation 17
Stage 1: PF-04856883 24 mg	Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 1	10010 milliliter (mL)	Geometric Coefficient of Variation 67

Secondary

Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 2

Time frame: predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 2	9550 mL	Geometric Coefficient of Variation 29
Stage 1: PF-04856883 4 mg	Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 2	NA mL	—
Stage 1: PF-04856883 8 mg	Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 2	NA mL	—
Stage 1: PF-04856883 12 mg	Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 2	NA mL	—

Secondary

Area Under the Concentration Time Curve From Time Zero to Time Tau (AUCtau) of PF-04856883: Stage 2

Area under the serum concentration-time curve from time 0 to tau (AUCtau), where tau was the dosing interval of 168 hours.

Time frame: predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168 hours postdose Day 1; predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168 hours postdose Day 22

Population: PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, 'n' signifies those participants who were evaluable at specified time point for each arm, respectively.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Area Under the Concentration Time Curve From Time Zero to Time Tau (AUCtau) of PF-04856883: Stage 2	Day 1 (n =5, 7, 7, 6)	85370 ng*hr/mL	Geometric Coefficient of Variation 38
Stage 1: PF-04856883 Placebo	Area Under the Concentration Time Curve From Time Zero to Time Tau (AUCtau) of PF-04856883: Stage 2	Day 22 (n =5, 7, 5, 6)	269000 ng*hr/mL	Geometric Coefficient of Variation 32
Stage 1: PF-04856883 4 mg	Area Under the Concentration Time Curve From Time Zero to Time Tau (AUCtau) of PF-04856883: Stage 2	Day 22 (n =5, 7, 5, 6)	377400 ng*hr/mL	Geometric Coefficient of Variation 28
Stage 1: PF-04856883 4 mg	Area Under the Concentration Time Curve From Time Zero to Time Tau (AUCtau) of PF-04856883: Stage 2	Day 1 (n =5, 7, 7, 6)	99780 ng*hr/mL	Geometric Coefficient of Variation 41
Stage 1: PF-04856883 8 mg	Area Under the Concentration Time Curve From Time Zero to Time Tau (AUCtau) of PF-04856883: Stage 2	Day 1 (n =5, 7, 7, 6)	89390 ng*hr/mL	Geometric Coefficient of Variation 35
Stage 1: PF-04856883 8 mg	Area Under the Concentration Time Curve From Time Zero to Time Tau (AUCtau) of PF-04856883: Stage 2	Day 22 (n =5, 7, 5, 6)	396300 ng*hr/mL	Geometric Coefficient of Variation 28
Stage 1: PF-04856883 12 mg	Area Under the Concentration Time Curve From Time Zero to Time Tau (AUCtau) of PF-04856883: Stage 2	Day 1 (n =5, 7, 7, 6)	91130 ng*hr/mL	Geometric Coefficient of Variation 27
Stage 1: PF-04856883 12 mg	Area Under the Concentration Time Curve From Time Zero to Time Tau (AUCtau) of PF-04856883: Stage 2	Day 22 (n =5, 7, 5, 6)	430500 ng*hr/mL	Geometric Coefficient of Variation 23

Secondary

Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) of PF-04856883: Stage 1

AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame: predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1

Population: PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) of PF-04856883: Stage 1	44920 nanogramhour per milliliter (nghr/mL)	Geometric Coefficient of Variation 112
Stage 1: PF-04856883 4 mg	Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) of PF-04856883: Stage 1	95190 nanogramhour per milliliter (nghr/mL)	Geometric Coefficient of Variation 76
Stage 1: PF-04856883 8 mg	Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) of PF-04856883: Stage 1	295200 nanogramhour per milliliter (nghr/mL)	Geometric Coefficient of Variation 46
Stage 1: PF-04856883 12 mg	Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) of PF-04856883: Stage 1	527100 nanogramhour per milliliter (nghr/mL)	Geometric Coefficient of Variation 53
Stage 1: PF-04856883 18 mg	Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) of PF-04856883: Stage 1	711300 nanogramhour per milliliter (nghr/mL)	Geometric Coefficient of Variation 13
Stage 1: PF-04856883 24 mg	Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) of PF-04856883: Stage 1	652000 nanogramhour per milliliter (nghr/mL)	Geometric Coefficient of Variation 50

Secondary

Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2

Time frame: Baseline, Day 8, 15, 22, 29 and 50

Population: Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, 'n' signifies those participants who were evaluable at specified time point for each arm, respectively.

Arm	Measure	Group	Value (MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 8 (n =7, 5, 7, 6, 6)	-0.10 mcg/mL	Standard Deviation 0.663
Stage 1: PF-04856883 Placebo	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	7.66 mcg/mL	Standard Deviation 4.351
Stage 1: PF-04856883 Placebo	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 7, 6)	0.40 mcg/mL	Standard Deviation 2.106
Stage 1: PF-04856883 Placebo	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 5)	0.36 mcg/mL	Standard Deviation 1.765
Stage 1: PF-04856883 Placebo	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 22 (n =7, 5, 7, 6, 6)	0.13 mcg/mL	Standard Deviation 1.289
Stage 1: PF-04856883 Placebo	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	-0.03 mcg/mL	Standard Deviation 1.376
Stage 1: PF-04856883 4 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 22 (n =7, 5, 7, 6, 6)	1.14 mcg/mL	Standard Deviation 0.518
Stage 1: PF-04856883 4 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 8 (n =7, 5, 7, 6, 6)	0.40 mcg/mL	Standard Deviation 0.962
Stage 1: PF-04856883 4 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	0.72 mcg/mL	Standard Deviation 1.512
Stage 1: PF-04856883 4 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	6.32 mcg/mL	Standard Deviation 3.517
Stage 1: PF-04856883 4 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 5)	1.46 mcg/mL	Standard Deviation 0.73
Stage 1: PF-04856883 4 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 7, 6)	0.38 mcg/mL	Standard Deviation 2.381
Stage 1: PF-04856883 8 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	8.09 mcg/mL	Standard Deviation 6.24
Stage 1: PF-04856883 8 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 8 (n =7, 5, 7, 6, 6)	0.41 mcg/mL	Standard Deviation 0.57
Stage 1: PF-04856883 8 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	1.21 mcg/mL	Standard Deviation 0.641
Stage 1: PF-04856883 8 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 22 (n =7, 5, 7, 6, 6)	1.73 mcg/mL	Standard Deviation 1.034
Stage 1: PF-04856883 8 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 5)	1.83 mcg/mL	Standard Deviation 1.241
Stage 1: PF-04856883 8 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 7, 6)	-0.30 mcg/mL	Standard Deviation 1.294
Stage 1: PF-04856883 12 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 22 (n =7, 5, 7, 6, 6)	0.95 mcg/mL	Standard Deviation 3.086
Stage 1: PF-04856883 12 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	0.32 mcg/mL	Standard Deviation 2.483
Stage 1: PF-04856883 12 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 8 (n =7, 5, 7, 6, 6)	-0.08 mcg/mL	Standard Deviation 1.599
Stage 1: PF-04856883 12 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 7, 6)	1.64 mcg/mL	Standard Deviation 2.985
Stage 1: PF-04856883 12 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	7.59 mcg/mL	Standard Deviation 5.538
Stage 1: PF-04856883 12 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 5)	1.50 mcg/mL	Standard Deviation 2.9
Stage 1: PF-04856883 18 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	3.95 mcg/mL	Standard Deviation 1.291
Stage 1: PF-04856883 18 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	0.63 mcg/mL	Standard Deviation 1.481
Stage 1: PF-04856883 18 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 5)	1.60 mcg/mL	Standard Deviation 2.827
Stage 1: PF-04856883 18 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 8 (n =7, 5, 7, 6, 6)	0.90 mcg/mL	Standard Deviation 0.502
Stage 1: PF-04856883 18 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 7, 6)	0.92 mcg/mL	Standard Deviation 2.076
Stage 1: PF-04856883 18 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 22 (n =7, 5, 7, 6, 6)	1.28 mcg/mL	Standard Deviation 2.046

Comparison: Day 8: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.p-value: 0.38780% CI: [-0.24, 1.21]Mixed meal tolerance test

Comparison: Day 15: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.p-value: 0.43480% CI: [-0.48, 1.95]Mixed meal tolerance test

Comparison: Day 22: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.p-value: 0.35880% CI: [-0.4, 2.4]Mixed meal tolerance test

Comparison: Day 29: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.p-value: 0.36280% CI: [-0.45, 2.63]Mixed meal tolerance test

Comparison: Day 50: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.p-value: 0.97980% CI: [-1.77, 1.7]Mixed meal tolerance test

Secondary

Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1

Time frame: Baseline, Day 8, 15 and 29

Arm	Measure	Group	Value (MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	8.17 microgram per milliliter (mcg/mL)	Standard Deviation 5.021
Stage 1: PF-04856883 Placebo	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 29 (n =15, 5, 5, 6, 7, 5, 7)	0.46 microgram per milliliter (mcg/mL)	Standard Deviation 1.608
Stage 1: PF-04856883 Placebo	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 7)	0.39 microgram per milliliter (mcg/mL)	Standard Deviation 0.895
Stage 1: PF-04856883 Placebo	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	0.38 microgram per milliliter (mcg/mL)	Standard Deviation 1.047
Stage 1: PF-04856883 4 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	0.42 microgram per milliliter (mcg/mL)	Standard Deviation 1.711
Stage 1: PF-04856883 4 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 7)	-0.36 microgram per milliliter (mcg/mL)	Standard Deviation 0.727
Stage 1: PF-04856883 4 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 29 (n =15, 5, 5, 6, 7, 5, 7)	-0.36 microgram per milliliter (mcg/mL)	Standard Deviation 0.82
Stage 1: PF-04856883 4 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	5.02 microgram per milliliter (mcg/mL)	Standard Deviation 2.831
Stage 1: PF-04856883 8 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	5.77 microgram per milliliter (mcg/mL)	Standard Deviation 1.306
Stage 1: PF-04856883 8 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	1.50 microgram per milliliter (mcg/mL)	Standard Deviation 1.321
Stage 1: PF-04856883 8 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 29 (n =15, 5, 5, 6, 7, 5, 7)	-0.52 microgram per milliliter (mcg/mL)	Standard Deviation 3.192
Stage 1: PF-04856883 8 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 7)	0.64 microgram per milliliter (mcg/mL)	Standard Deviation 0.639
Stage 1: PF-04856883 12 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 29 (n =15, 5, 5, 6, 7, 5, 7)	-0.62 microgram per milliliter (mcg/mL)	Standard Deviation 1.492
Stage 1: PF-04856883 12 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	-0.32 microgram per milliliter (mcg/mL)	Standard Deviation 1.143
Stage 1: PF-04856883 12 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	5.35 microgram per milliliter (mcg/mL)	Standard Deviation 3.683
Stage 1: PF-04856883 12 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 7)	0.15 microgram per milliliter (mcg/mL)	Standard Deviation 0.596
Stage 1: PF-04856883 18 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 29 (n =15, 5, 5, 6, 7, 5, 7)	0.97 microgram per milliliter (mcg/mL)	Standard Deviation 1.467
Stage 1: PF-04856883 18 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 7)	0.73 microgram per milliliter (mcg/mL)	Standard Deviation 0.632
Stage 1: PF-04856883 18 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	6.20 microgram per milliliter (mcg/mL)	Standard Deviation 5.44
Stage 1: PF-04856883 18 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	1.07 microgram per milliliter (mcg/mL)	Standard Deviation 1.111
Stage 1: PF-04856883 24 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 7)	0.00 microgram per milliliter (mcg/mL)	Standard Deviation 1.584
Stage 1: PF-04856883 24 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	12.04 microgram per milliliter (mcg/mL)	Standard Deviation 5.133
Stage 1: PF-04856883 24 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	0.32 microgram per milliliter (mcg/mL)	Standard Deviation 1.608
Stage 1: PF-04856883 24 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 29 (n =15, 5, 5, 6, 7, 5, 7)	0.36 microgram per milliliter (mcg/mL)	Standard Deviation 1.499
Stage 1: PF-04856883 36 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 7)	0.97 microgram per milliliter (mcg/mL)	Standard Deviation 0.629
Stage 1: PF-04856883 36 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 29 (n =15, 5, 5, 6, 7, 5, 7)	0.66 microgram per milliliter (mcg/mL)	Standard Deviation 1.11
Stage 1: PF-04856883 36 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	1.17 microgram per milliliter (mcg/mL)	Standard Deviation 0.78
Stage 1: PF-04856883 36 mg	Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	11.84 microgram per milliliter (mcg/mL)	Standard Deviation 8.122

Secondary

Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2

A normalized area under the curve (NAUC) were computed by dividing the AUC by the amount of time between the last time point captured and the first time point captured.

Time frame: Baseline, Day 30

Arm	Measure	Group	Value (MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2	Baseline (n =7, 5, 7, 7 ,6)	166.19 mg/dL	Standard Deviation 35.437
Stage 1: PF-04856883 Placebo	Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2	Change at Day 30 (n =7, 5, 7, 6 ,5)	172.36 mg/dL	Standard Deviation 38.825
Stage 1: PF-04856883 4 mg	Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2	Baseline (n =7, 5, 7, 7 ,6)	212.43 mg/dL	Standard Deviation 52.764
Stage 1: PF-04856883 4 mg	Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2	Change at Day 30 (n =7, 5, 7, 6 ,5)	191.20 mg/dL	Standard Deviation 43.953
Stage 1: PF-04856883 8 mg	Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2	Baseline (n =7, 5, 7, 7 ,6)	205.56 mg/dL	Standard Deviation 51.907
Stage 1: PF-04856883 8 mg	Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2	Change at Day 30 (n =7, 5, 7, 6 ,5)	172.24 mg/dL	Standard Deviation 48.067
Stage 1: PF-04856883 12 mg	Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2	Change at Day 30 (n =7, 5, 7, 6 ,5)	174.08 mg/dL	Standard Deviation 41.437
Stage 1: PF-04856883 12 mg	Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2	Baseline (n =7, 5, 7, 7 ,6)	202.43 mg/dL	Standard Deviation 38.9
Stage 1: PF-04856883 18 mg	Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2	Baseline (n =7, 5, 7, 7 ,6)	186.13 mg/dL	Standard Deviation 33.839
Stage 1: PF-04856883 18 mg	Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2	Change at Day 30 (n =7, 5, 7, 6 ,5)	192.87 mg/dL	Standard Deviation 58.037

Comparison: Day 30p-value: 0.03480% CI: [-54.2, -14.16]Mixed meal tolerance test

Comparison: Day 30p-value: 0.04480% CI: [-54.5, -12.84]Mixed meal tolerance test

Comparison: Day 30p-value: 0.85780% CI: [-24.16, 18.31]Mixed meal tolerance test

Comparison: Day 30p-value: 0.21980% CI: [-43.26, 0.93]Mixed meal tolerance test

Secondary

Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2

Change from baseline in post-prandial area under the plasma C-peptide concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.

Time frame: Baseline, Day 3, 15, 24, 29 and 50

Arm	Measure	Group	Value (MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 6, 5)	-0.17 ng*hr/mL	Standard Deviation 1.978
Stage 1: PF-04856883 Placebo	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 5)	0.10 ng*hr/mL	Standard Deviation 3.864
Stage 1: PF-04856883 Placebo	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 24 (n =7, 4, 7, 6, 6)	0.55 ng*hr/mL	Standard Deviation 3.518
Stage 1: PF-04856883 Placebo	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 3 (n =7, 5, 7, 7, 6)	1.68 ng*hr/mL	Standard Deviation 2.182
Stage 1: PF-04856883 Placebo	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	-1.65 ng*hr/mL	Standard Deviation 1.493
Stage 1: PF-04856883 Placebo	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	13.47 ng*hr/mL	Standard Deviation 4.315
Stage 1: PF-04856883 4 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	14.59 ng*hr/mL	Standard Deviation 4.205
Stage 1: PF-04856883 4 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 24 (n =7, 4, 7, 6, 6)	0.71 ng*hr/mL	Standard Deviation 4.312
Stage 1: PF-04856883 4 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	-1.55 ng*hr/mL	Standard Deviation 2.821
Stage 1: PF-04856883 4 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 6, 5)	-1.83 ng*hr/mL	Standard Deviation 2.015
Stage 1: PF-04856883 4 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 5)	-0.07 ng*hr/mL	Standard Deviation 2.545
Stage 1: PF-04856883 4 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 3 (n =7, 5, 7, 7, 6)	1.89 ng*hr/mL	Standard Deviation 4.705
Stage 1: PF-04856883 8 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 5)	-0.59 ng*hr/mL	Standard Deviation 4.144
Stage 1: PF-04856883 8 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	15.63 ng*hr/mL	Standard Deviation 4.293
Stage 1: PF-04856883 8 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 3 (n =7, 5, 7, 7, 6)	0.50 ng*hr/mL	Standard Deviation 4.757
Stage 1: PF-04856883 8 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 24 (n =7, 4, 7, 6, 6)	-0.99 ng*hr/mL	Standard Deviation 6.22
Stage 1: PF-04856883 8 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 6, 5)	-4.10 ng*hr/mL	Standard Deviation 5.265
Stage 1: PF-04856883 8 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	-1.92 ng*hr/mL	Standard Deviation 6.93
Stage 1: PF-04856883 12 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 6, 5)	1.06 ng*hr/mL	Standard Deviation 1.474
Stage 1: PF-04856883 12 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	-0.17 ng*hr/mL	Standard Deviation 4.135
Stage 1: PF-04856883 12 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 5)	0.59 ng*hr/mL	Standard Deviation 2.733
Stage 1: PF-04856883 12 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	11.74 ng*hr/mL	Standard Deviation 5.21
Stage 1: PF-04856883 12 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 3 (n =7, 5, 7, 7, 6)	3.16 ng*hr/mL	Standard Deviation 1.613
Stage 1: PF-04856883 12 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 24 (n =7, 4, 7, 6, 6)	1.63 ng*hr/mL	Standard Deviation 2.994
Stage 1: PF-04856883 18 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 6, 5)	-2.90 ng*hr/mL	Standard Deviation 3.711
Stage 1: PF-04856883 18 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 3 (n =7, 5, 7, 7, 6)	3.49 ng*hr/mL	Standard Deviation 4.452
Stage 1: PF-04856883 18 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 5)	0.41 ng*hr/mL	Standard Deviation 2.09
Stage 1: PF-04856883 18 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 24 (n =7, 4, 7, 6, 6)	1.21 ng*hr/mL	Standard Deviation 5.784
Stage 1: PF-04856883 18 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	-0.50 ng*hr/mL	Standard Deviation 4.871
Stage 1: PF-04856883 18 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	14.14 ng*hr/mL	Standard Deviation 5.211

Secondary

Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1

Change from baseline in post-prandial area under the plasma C-peptide concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.

Time frame: Baseline, Day 3 and 8

Arm	Measure	Group	Value (MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 4, 5, 6, 7, 5, 6)	0.79 ng*hr/mL	Standard Deviation 2.864
Stage 1: PF-04856883 Placebo	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	2.15 ng*hr/mL	Standard Deviation 3.653
Stage 1: PF-04856883 Placebo	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7,5, 7)	15.53 ng*hr/mL	Standard Deviation 5.332
Stage 1: PF-04856883 4 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	0.69 ng*hr/mL	Standard Deviation 1.465
Stage 1: PF-04856883 4 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 4, 5, 6, 7, 5, 6)	1.06 ng*hr/mL	Standard Deviation 1.806
Stage 1: PF-04856883 4 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7,5, 7)	16.63 ng*hr/mL	Standard Deviation 7.743
Stage 1: PF-04856883 8 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7,5, 7)	16.43 ng*hr/mL	Standard Deviation 4.306
Stage 1: PF-04856883 8 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 4, 5, 6, 7, 5, 6)	0.83 ng*hr/mL	Standard Deviation 1.651
Stage 1: PF-04856883 8 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	1.65 ng*hr/mL	Standard Deviation 4.958
Stage 1: PF-04856883 12 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7,5, 7)	16.80 ng*hr/mL	Standard Deviation 5.711
Stage 1: PF-04856883 12 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 4, 5, 6, 7, 5, 6)	-2.74 ng*hr/mL	Standard Deviation 1.38
Stage 1: PF-04856883 12 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	1.05 ng*hr/mL	Standard Deviation 1.885
Stage 1: PF-04856883 18 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 4, 5, 6, 7, 5, 6)	1.70 ng*hr/mL	Standard Deviation 1.544
Stage 1: PF-04856883 18 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	4.30 ng*hr/mL	Standard Deviation 4.102
Stage 1: PF-04856883 18 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7,5, 7)	10.64 ng*hr/mL	Standard Deviation 1.156
Stage 1: PF-04856883 24 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7,5, 7)	16.17 ng*hr/mL	Standard Deviation 4.531
Stage 1: PF-04856883 24 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 4, 5, 6, 7, 5, 6)	-0.45 ng*hr/mL	Standard Deviation 2.883
Stage 1: PF-04856883 24 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	5.34 ng*hr/mL	Standard Deviation 2.584
Stage 1: PF-04856883 36 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7,5, 7)	18.37 ng*hr/mL	Standard Deviation 7.395
Stage 1: PF-04856883 36 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	2.34 ng*hr/mL	Standard Deviation 4.333
Stage 1: PF-04856883 36 mg	Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 4, 5, 6, 7, 5, 6)	-0.38 ng*hr/mL	Standard Deviation 1.565

Secondary

Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1

Time frame: Baseline, Day 2, 4, 6, 15, 22 and 29

Arm	Measure	Group	Value (MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 22 (n =14, 4, 5, 6, 6, 5, 7)	11.00 milligram per deciliter (mg/dL)	Standard Deviation 28.205
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	161.67 milligram per deciliter (mg/dL)	Standard Deviation 27.102
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 6 (n =15, 5, 4, 6, 7, 5, 7)	18.80 milligram per deciliter (mg/dL)	Standard Deviation 29.547
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 2 (n =15, 5, 6, 6, 7, 5, 7)	3.13 milligram per deciliter (mg/dL)	Standard Deviation 11.807
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 4 (n =15, 5, 5, 6, 7, 5, 6)	2.73 milligram per deciliter (mg/dL)	Standard Deviation 17.161
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	12.13 milligram per deciliter (mg/dL)	Standard Deviation 32.822
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 29 (n =14, 5, 5, 6, 7, 5, 7)	22.00 milligram per deciliter (mg/dL)	Standard Deviation 33.439
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	219.60 milligram per deciliter (mg/dL)	Standard Deviation 44.557
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 2 (n =15, 5, 6, 6, 7, 5, 7)	13.60 milligram per deciliter (mg/dL)	Standard Deviation 32.393
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 4 (n =15, 5, 5, 6, 7, 5, 6)	19.60 milligram per deciliter (mg/dL)	Standard Deviation 35.683
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 29 (n =14, 5, 5, 6, 7, 5, 7)	1.60 milligram per deciliter (mg/dL)	Standard Deviation 27.763
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 22 (n =14, 4, 5, 6, 6, 5, 7)	23.75 milligram per deciliter (mg/dL)	Standard Deviation 61.163
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	-13.80 milligram per deciliter (mg/dL)	Standard Deviation 46.949
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 6 (n =15, 5, 4, 6, 7, 5, 7)	26.40 milligram per deciliter (mg/dL)	Standard Deviation 32.377
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	23.80 milligram per deciliter (mg/dL)	Standard Deviation 56.857
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 6 (n =15, 5, 4, 6, 7, 5, 7)	10.25 milligram per deciliter (mg/dL)	Standard Deviation 29.056
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 2 (n =15, 5, 6, 6, 7, 5, 7)	-18.67 milligram per deciliter (mg/dL)	Standard Deviation 21.011
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	171.17 milligram per deciliter (mg/dL)	Standard Deviation 23.752
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 4 (n =15, 5, 5, 6, 7, 5, 6)	-12.40 milligram per deciliter (mg/dL)	Standard Deviation 17.358
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 22 (n =14, 4, 5, 6, 6, 5, 7)	33.40 milligram per deciliter (mg/dL)	Standard Deviation 76.064
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 29 (n =14, 5, 5, 6, 7, 5, 7)	27.80 milligram per deciliter (mg/dL)	Standard Deviation 29.575
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 22 (n =14, 4, 5, 6, 6, 5, 7)	11.17 milligram per deciliter (mg/dL)	Standard Deviation 26.446
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	174.00 milligram per deciliter (mg/dL)	Standard Deviation 48.949
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 2 (n =15, 5, 6, 6, 7, 5, 7)	-20.50 milligram per deciliter (mg/dL)	Standard Deviation 20.433
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	19.33 milligram per deciliter (mg/dL)	Standard Deviation 16.476
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 29 (n =14, 5, 5, 6, 7, 5, 7)	0.33 milligram per deciliter (mg/dL)	Standard Deviation 16.978
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 4 (n =15, 5, 5, 6, 7, 5, 6)	-10.33 milligram per deciliter (mg/dL)	Standard Deviation 15.744
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 6 (n =15, 5, 4, 6, 7, 5, 7)	-8.33 milligram per deciliter (mg/dL)	Standard Deviation 27.156
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 6 (n =15, 5, 4, 6, 7, 5, 7)	-6.29 milligram per deciliter (mg/dL)	Standard Deviation 15.85
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	168.57 milligram per deciliter (mg/dL)	Standard Deviation 38.336
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 22 (n =14, 4, 5, 6, 6, 5, 7)	2.17 milligram per deciliter (mg/dL)	Standard Deviation 15.065
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	8.00 milligram per deciliter (mg/dL)	Standard Deviation 21.223
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 2 (n =15, 5, 6, 6, 7, 5, 7)	-22.14 milligram per deciliter (mg/dL)	Standard Deviation 34.09
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 4 (n =15, 5, 5, 6, 7, 5, 6)	-30.71 milligram per deciliter (mg/dL)	Standard Deviation 13.841
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 29 (n =14, 5, 5, 6, 7, 5, 7)	1.57 milligram per deciliter (mg/dL)	Standard Deviation 21.22
Stage 1: PF-04856883 24 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 6 (n =15, 5, 4, 6, 7, 5, 7)	-16.80 milligram per deciliter (mg/dL)	Standard Deviation 19.176
Stage 1: PF-04856883 24 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	145.60 milligram per deciliter (mg/dL)	Standard Deviation 21.606
Stage 1: PF-04856883 24 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 2 (n =15, 5, 6, 6, 7, 5, 7)	-35.00 milligram per deciliter (mg/dL)	Standard Deviation 12.369
Stage 1: PF-04856883 24 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 29 (n =14, 5, 5, 6, 7, 5, 7)	-3.80 milligram per deciliter (mg/dL)	Standard Deviation 22.643
Stage 1: PF-04856883 24 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 4 (n =15, 5, 5, 6, 7, 5, 6)	-27.00 milligram per deciliter (mg/dL)	Standard Deviation 8.803
Stage 1: PF-04856883 24 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 22 (n =14, 4, 5, 6, 6, 5, 7)	1.20 milligram per deciliter (mg/dL)	Standard Deviation 18.847
Stage 1: PF-04856883 24 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	3.40 milligram per deciliter (mg/dL)	Standard Deviation 27.309
Stage 1: PF-04856883 36 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 22 (n =14, 4, 5, 6, 6, 5, 7)	-0.57 milligram per deciliter (mg/dL)	Standard Deviation 13.377
Stage 1: PF-04856883 36 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 29 (n =14, 5, 5, 6, 7, 5, 7)	-2.29 milligram per deciliter (mg/dL)	Standard Deviation 19.551
Stage 1: PF-04856883 36 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 2 (n =15, 5, 6, 6, 7, 5, 7)	-29.71 milligram per deciliter (mg/dL)	Standard Deviation 30.804
Stage 1: PF-04856883 36 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 4 (n =15, 5, 5, 6, 7, 5, 6)	-28.33 milligram per deciliter (mg/dL)	Standard Deviation 21.942
Stage 1: PF-04856883 36 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	158.14 milligram per deciliter (mg/dL)	Standard Deviation 35.362
Stage 1: PF-04856883 36 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 6 (n =15, 5, 4, 6, 7, 5, 7)	-16.14 milligram per deciliter (mg/dL)	Standard Deviation 22.319
Stage 1: PF-04856883 36 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	-2.71 milligram per deciliter (mg/dL)	Standard Deviation 16.53

Secondary

Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2

Time frame: Baseline, Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43

Arm	Measure	Group	Value (MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 25 (n =7, 5, 6, 6, 5)	13.43 mg/dL	Standard Deviation 13.113
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 22 (n =7, 4, 7, 6, 6)	13.29 mg/dL	Standard Deviation 15.294
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Baseline (n =7, 5, 7, 7, 6)	148.00 mg/dL	Standard Deviation 33.317
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 23 (n =7, 4, 6, 6, 5)	7.71 mg/dL	Standard Deviation 23.894
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 8 (n =6, 5, 7, 5, 6)	2.50 mg/dL	Standard Deviation 17.627
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 2 (n =5, 4, 7, 7, 5)	3.00 mg/dL	Standard Deviation 15.281
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 43 (n =7, 5, 5, 6, 6)	18.71 mg/dL	Standard Deviation 22.552
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 6 (n =7, 4, 7, 7, 6)	-1.71 mg/dL	Standard Deviation 40.24
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 4 (n =5, 5, 7, 6, 6)	7.60 mg/dL	Standard Deviation 6.427
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 36 (n =6, 5, 7, 6, 6)	-10.50 mg/dL	Standard Deviation 32.415
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 30 (n =7, 5, 7, 6, 5)	2.43 mg/dL	Standard Deviation 12.739
Stage 1: PF-04856883 Placebo	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 27 (n =7, 5, 6, 6, 5)	8.57 mg/dL	Standard Deviation 21.11
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 22 (n =7, 4, 7, 6, 6)	-4.25 mg/dL	Standard Deviation 13.817
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Baseline (n =7, 5, 7, 7, 6)	186.80 mg/dL	Standard Deviation 23.059
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 2 (n =5, 4, 7, 7, 5)	-26.75 mg/dL	Standard Deviation 15.108
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 25 (n =7, 5, 6, 6, 5)	-16.60 mg/dL	Standard Deviation 43.443
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 30 (n =7, 5, 7, 6, 5)	-14.20 mg/dL	Standard Deviation 17.908
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 36 (n =6, 5, 7, 6, 6)	0.40 mg/dL	Standard Deviation 37.846
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 4 (n =5, 5, 7, 6, 6)	-14.80 mg/dL	Standard Deviation 24.284
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 6 (n =7, 4, 7, 7, 6)	5.75 mg/dL	Standard Deviation 14.08
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 8 (n =6, 5, 7, 5, 6)	4.20 mg/dL	Standard Deviation 19.967
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 23 (n =7, 4, 6, 6, 5)	-27.25 mg/dL	Standard Deviation 27.293
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 27 (n =7, 5, 6, 6, 5)	-21.60 mg/dL	Standard Deviation 15.821
Stage 1: PF-04856883 4 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 43 (n =7, 5, 5, 6, 6)	12.80 mg/dL	Standard Deviation 29.064
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 27 (n =7, 5, 6, 6, 5)	-37.33 mg/dL	Standard Deviation 17.963
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 8 (n =6, 5, 7, 5, 6)	-37.43 mg/dL	Standard Deviation 42.383
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 30 (n =7, 5, 7, 6, 5)	-22.29 mg/dL	Standard Deviation 26.171
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 36 (n =6, 5, 7, 6, 6)	1.86 mg/dL	Standard Deviation 25.373
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 43 (n =7, 5, 5, 6, 6)	13.20 mg/dL	Standard Deviation 17.254
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Baseline (n =7, 5, 7, 7, 6)	191.14 mg/dL	Standard Deviation 56.153
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 4 (n =5, 5, 7, 6, 6)	-14.86 mg/dL	Standard Deviation 48.657
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 2 (n =5, 4, 7, 7, 5)	-15.14 mg/dL	Standard Deviation 21.217
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 23 (n =7, 4, 6, 6, 5)	-40.33 mg/dL	Standard Deviation 18.327
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 6 (n =7, 4, 7, 7, 6)	-44.86 mg/dL	Standard Deviation 38.451
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 22 (n =7, 4, 7, 6, 6)	-39.57 mg/dL	Standard Deviation 25.468
Stage 1: PF-04856883 8 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 25 (n =7, 5, 6, 6, 5)	-44.67 mg/dL	Standard Deviation 27.667
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 36 (n =6, 5, 7, 6, 6)	-5.83 mg/dL	Standard Deviation 32.009
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 22 (n =7, 4, 7, 6, 6)	-14.17 mg/dL	Standard Deviation 38.27
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 43 (n =7, 5, 5, 6, 6)	-1.17 mg/dL	Standard Deviation 41.787
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 2 (n =5, 4, 7, 7, 5)	-23.43 mg/dL	Standard Deviation 35.142
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 4 (n =5, 5, 7, 6, 6)	-20.33 mg/dL	Standard Deviation 22.818
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 23 (n =7, 4, 6, 6, 5)	-17.50 mg/dL	Standard Deviation 73.519
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 8 (n =6, 5, 7, 5, 6)	2.60 mg/dL	Standard Deviation 73.449
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 25 (n =7, 5, 6, 6, 5)	-23.33 mg/dL	Standard Deviation 52.936
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 6 (n =7, 4, 7, 7, 6)	-8.00 mg/dL	Standard Deviation 42.942
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 27 (n =7, 5, 6, 6, 5)	-34.67 mg/dL	Standard Deviation 35.803
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 30 (n =7, 5, 7, 6, 5)	-9.33 mg/dL	Standard Deviation 32.898
Stage 1: PF-04856883 12 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Baseline (n =7, 5, 7, 7, 6)	187.29 mg/dL	Standard Deviation 45.756
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 2 (n =5, 4, 7, 7, 5)	-10.40 mg/dL	Standard Deviation 18.461
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 36 (n =6, 5, 7, 6, 6)	27.67 mg/dL	Standard Deviation 59.594
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 27 (n =7, 5, 6, 6, 5)	12.00 mg/dL	Standard Deviation 71.039
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 43 (n =7, 5, 5, 6, 6)	8.33 mg/dL	Standard Deviation 18.991
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 6 (n =7, 4, 7, 7, 6)	-15.83 mg/dL	Standard Deviation 8.909
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 23 (n =7, 4, 6, 6, 5)	-24.00 mg/dL	Standard Deviation 29.967
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 8 (n =6, 5, 7, 5, 6)	24.50 mg/dL	Standard Deviation 47.618
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 22 (n =7, 4, 7, 6, 6)	-0.33 mg/dL	Standard Deviation 51.181
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 4 (n =5, 5, 7, 6, 6)	-1.50 mg/dL	Standard Deviation 27.384
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Baseline (n =7, 5, 7, 7, 6)	158.50 mg/dL	Standard Deviation 18.447
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 25 (n =7, 5, 6, 6, 5)	-16.20 mg/dL	Standard Deviation 36.513
Stage 1: PF-04856883 18 mg	Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2	Change at Day 30 (n =7, 5, 7, 6, 5)	15.40 mg/dL	Standard Deviation 37.964

Secondary

Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2

Time frame: Baseline, Day 8, 15, 22, 29 and 50

Arm	Measure	Group	Value (MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	281.14 mcmol/L	Standard Deviation 57.875
Stage 1: PF-04856883 Placebo	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	-1.86 mcmol/L	Standard Deviation 21.146
Stage 1: PF-04856883 Placebo	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 22 (n =7, 5, 7, 6, 6)	-7.43 mcmol/L	Standard Deviation 13.176
Stage 1: PF-04856883 Placebo	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 4)	-4.43 mcmol/L	Standard Deviation 27.098
Stage 1: PF-04856883 Placebo	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 7, 6)	-6.86 mcmol/L	Standard Deviation 20.732
Stage 1: PF-04856883 Placebo	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 8 (n =7, 5, 7, 6, 6)	-5.29 mcmol/L	Standard Deviation 19.678
Stage 1: PF-04856883 4 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 4)	-26.60 mcmol/L	Standard Deviation 22.612
Stage 1: PF-04856883 4 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 22 (n =7, 5, 7, 6, 6)	-18.20 mcmol/L	Standard Deviation 20.462
Stage 1: PF-04856883 4 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	309.40 mcmol/L	Standard Deviation 47.6
Stage 1: PF-04856883 4 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 7, 6)	-8.80 mcmol/L	Standard Deviation 14.446
Stage 1: PF-04856883 4 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	-8.20 mcmol/L	Standard Deviation 15.707
Stage 1: PF-04856883 4 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 8 (n =7, 5, 7, 6, 6)	-8.20 mcmol/L	Standard Deviation 11.1
Stage 1: PF-04856883 8 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 8 (n =7, 5, 7, 6, 6)	-12.14 mcmol/L	Standard Deviation 12.668
Stage 1: PF-04856883 8 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	-39.29 mcmol/L	Standard Deviation 21.077
Stage 1: PF-04856883 8 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 7, 6)	-6.43 mcmol/L	Standard Deviation 20.871
Stage 1: PF-04856883 8 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 22 (n =7, 5, 7, 6, 6)	-37.86 mcmol/L	Standard Deviation 19.945
Stage 1: PF-04856883 8 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 4)	-37.57 mcmol/L	Standard Deviation 14.976
Stage 1: PF-04856883 8 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	301.14 mcmol/L	Standard Deviation 43.69
Stage 1: PF-04856883 12 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 7, 6)	-12.43 mcmol/L	Standard Deviation 26.732
Stage 1: PF-04856883 12 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 4)	-32.67 mcmol/L	Standard Deviation 28.507
Stage 1: PF-04856883 12 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 8 (n =7, 5, 7, 6, 6)	-9.17 mcmol/L	Standard Deviation 23.043
Stage 1: PF-04856883 12 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	-11.67 mcmol/L	Standard Deviation 24.047
Stage 1: PF-04856883 12 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	291.29 mcmol/L	Standard Deviation 37.911
Stage 1: PF-04856883 12 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 22 (n =7, 5, 7, 6, 6)	-24.67 mcmol/L	Standard Deviation 20.925
Stage 1: PF-04856883 18 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 7, 6)	-5.67 mcmol/L	Standard Deviation 31.258
Stage 1: PF-04856883 18 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	303.67 mcmol/L	Standard Deviation 47.272
Stage 1: PF-04856883 18 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 4)	-41.00 mcmol/L	Standard Deviation 29.855
Stage 1: PF-04856883 18 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 22 (n =7, 5, 7, 6, 6)	-27.50 mcmol/L	Standard Deviation 25.399
Stage 1: PF-04856883 18 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 8 (n =7, 5, 7, 6, 6)	-10.17 mcmol/L	Standard Deviation 21.72
Stage 1: PF-04856883 18 mg	Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	-14.67 mcmol/L	Standard Deviation 33.037

Secondary

Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1

Time frame: Baseline, Day 8, 15 and 29

Arm	Measure	Group	Value (MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 7)	1.13 micromole per liter (mcmol/L)	Standard Deviation 14.461
Stage 1: PF-04856883 Placebo	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	270.60 micromole per liter (mcmol/L)	Standard Deviation 34.618
Stage 1: PF-04856883 Placebo	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 29 (n =15, 5, 5, 6, 7, 5, 7)	0.93 micromole per liter (mcmol/L)	Standard Deviation 19.627
Stage 1: PF-04856883 Placebo	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	-5.67 micromole per liter (mcmol/L)	Standard Deviation 17.839
Stage 1: PF-04856883 4 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	-20.40 micromole per liter (mcmol/L)	Standard Deviation 25.393
Stage 1: PF-04856883 4 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 7)	20.20 micromole per liter (mcmol/L)	Standard Deviation 10.986
Stage 1: PF-04856883 4 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 29 (n =15, 5, 5, 6, 7, 5, 7)	8.40 micromole per liter (mcmol/L)	Standard Deviation 30.876
Stage 1: PF-04856883 4 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	289.20 micromole per liter (mcmol/L)	Standard Deviation 48.329
Stage 1: PF-04856883 8 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	-16.40 micromole per liter (mcmol/L)	Standard Deviation 13.502
Stage 1: PF-04856883 8 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 7)	4.20 micromole per liter (mcmol/L)	Standard Deviation 18.295
Stage 1: PF-04856883 8 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	279.67 micromole per liter (mcmol/L)	Standard Deviation 30.507
Stage 1: PF-04856883 8 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 29 (n =15, 5, 5, 6, 7, 5, 7)	7.20 micromole per liter (mcmol/L)	Standard Deviation 29.66
Stage 1: PF-04856883 12 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	304.83 micromole per liter (mcmol/L)	Standard Deviation 45.155
Stage 1: PF-04856883 12 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	-9.17 micromole per liter (mcmol/L)	Standard Deviation 25.135
Stage 1: PF-04856883 12 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 7)	5.67 micromole per liter (mcmol/L)	Standard Deviation 13.095
Stage 1: PF-04856883 12 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 29 (n =15, 5, 5, 6, 7, 5, 7)	-4.50 micromole per liter (mcmol/L)	Standard Deviation 16.109
Stage 1: PF-04856883 18 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	263.43 micromole per liter (mcmol/L)	Standard Deviation 34.942
Stage 1: PF-04856883 18 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	13.33 micromole per liter (mcmol/L)	Standard Deviation 24.188
Stage 1: PF-04856883 18 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 29 (n =15, 5, 5, 6, 7, 5, 7)	15.86 micromole per liter (mcmol/L)	Standard Deviation 24.024
Stage 1: PF-04856883 18 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 7)	4.29 micromole per liter (mcmol/L)	Standard Deviation 16.72
Stage 1: PF-04856883 24 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	259.80 micromole per liter (mcmol/L)	Standard Deviation 53.644
Stage 1: PF-04856883 24 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 29 (n =15, 5, 5, 6, 7, 5, 7)	1.40 micromole per liter (mcmol/L)	Standard Deviation 17.344
Stage 1: PF-04856883 24 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 7)	-13.60 micromole per liter (mcmol/L)	Standard Deviation 23.554
Stage 1: PF-04856883 24 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	-9.60 micromole per liter (mcmol/L)	Standard Deviation 22.267
Stage 1: PF-04856883 36 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 29 (n =15, 5, 5, 6, 7, 5, 7)	-4.43 micromole per liter (mcmol/L)	Standard Deviation 18.867
Stage 1: PF-04856883 36 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	273.71 micromole per liter (mcmol/L)	Standard Deviation 36.036
Stage 1: PF-04856883 36 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 7)	-12.29 micromole per liter (mcmol/L)	Standard Deviation 10.579
Stage 1: PF-04856883 36 mg	Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1	Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)	-3.00 micromole per liter (mcmol/L)	Standard Deviation 11.165

Secondary

Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2

Change from baseline in post-prandial plasma insulin AUC under the plasma insulin concentration versus time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.

Time frame: Baseline, Day 3, 15, 24, 29 and 50

Arm	Measure	Group	Value (MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 5)	8.25 mU*hr/L	Standard Deviation 55.799
Stage 1: PF-04856883 Placebo	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	-16.77 mU*hr/L	Standard Deviation 20.53
Stage 1: PF-04856883 Placebo	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	175.26 mU*hr/L	Standard Deviation 62.218
Stage 1: PF-04856883 Placebo	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 3 (n =7, 5, 7, 7, 6)	38.32 mU*hr/L	Standard Deviation 62.135
Stage 1: PF-04856883 Placebo	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 24 (n =7, 4, 7, 6, 6)	0.23 mU*hr/L	Standard Deviation 55.174
Stage 1: PF-04856883 Placebo	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 6, 5)	8.14 mU*hr/L	Standard Deviation 29.909
Stage 1: PF-04856883 4 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 6, 5)	-16.64 mU*hr/L	Standard Deviation 33.133
Stage 1: PF-04856883 4 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 3 (n =7, 5, 7, 7, 6)	13.29 mU*hr/L	Standard Deviation 55.764
Stage 1: PF-04856883 4 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	-39.16 mU*hr/L	Standard Deviation 42.93
Stage 1: PF-04856883 4 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	176.65 mU*hr/L	Standard Deviation 76.04
Stage 1: PF-04856883 4 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 24 (n =7, 4, 7, 6, 6)	-15.19 mU*hr/L	Standard Deviation 38.9
Stage 1: PF-04856883 4 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 5)	3.98 mU*hr/L	Standard Deviation 11.218
Stage 1: PF-04856883 8 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 5)	12.71 mU*hr/L	Standard Deviation 115.095
Stage 1: PF-04856883 8 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 24 (n =7, 4, 7, 6, 6)	6.87 mU*hr/L	Standard Deviation 184.83
Stage 1: PF-04856883 8 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	-10.07 mU*hr/L	Standard Deviation 172.044
Stage 1: PF-04856883 8 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 3 (n =7, 5, 7, 7, 6)	19.50 mU*hr/L	Standard Deviation 134.651
Stage 1: PF-04856883 8 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	267.29 mU*hr/L	Standard Deviation 111.497
Stage 1: PF-04856883 8 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 6, 5)	-57.14 mU*hr/L	Standard Deviation 116.193
Stage 1: PF-04856883 12 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 3 (n =7, 5, 7, 7, 6)	27.99 mU*hr/L	Standard Deviation 32.655
Stage 1: PF-04856883 12 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 5)	-1.61 mU*hr/L	Standard Deviation 85.866
Stage 1: PF-04856883 12 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 24 (n =7, 4, 7, 6, 6)	4.18 mU*hr/L	Standard Deviation 51.903
Stage 1: PF-04856883 12 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	162.96 mU*hr/L	Standard Deviation 111.688
Stage 1: PF-04856883 12 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	-51.69 mU*hr/L	Standard Deviation 77.925
Stage 1: PF-04856883 12 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 6, 5)	49.27 mU*hr/L	Standard Deviation 81.874
Stage 1: PF-04856883 18 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 24 (n =7, 4, 7, 6, 6)	60.11 mU*hr/L	Standard Deviation 189.287
Stage 1: PF-04856883 18 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 29 (n =7, 5, 7, 6, 5)	15.70 mU*hr/L	Standard Deviation 38.476
Stage 1: PF-04856883 18 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline (n =7, 5, 7, 7, 6)	190.64 mU*hr/L	Standard Deviation 83.945
Stage 1: PF-04856883 18 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 50 (n =7, 5, 7, 6, 5)	-26.78 mU*hr/L	Standard Deviation 81.518
Stage 1: PF-04856883 18 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 15 (n =7, 5, 7, 6, 6)	-24.36 mU*hr/L	Standard Deviation 85.633
Stage 1: PF-04856883 18 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 3 (n =7, 5, 7, 7, 6)	87.67 mU*hr/L	Standard Deviation 124.052

Secondary

Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1

Time frame: Baseline, Day 3 and 8

Arm	Measure	Group	Value (MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 4, 5, 6, 7, 5, 6)	34.23 milliUnithour per liter (mUhr/L)	Standard Deviation 103.279
Stage 1: PF-04856883 Placebo	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	68.79 milliUnithour per liter (mUhr/L)	Standard Deviation 115.555
Stage 1: PF-04856883 Placebo	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	222.18 milliUnithour per liter (mUhr/L)	Standard Deviation 139.981
Stage 1: PF-04856883 4 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 4, 5, 6, 7, 5, 6)	22.05 milliUnithour per liter (mUhr/L)	Standard Deviation 89.419
Stage 1: PF-04856883 4 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	227.07 milliUnithour per liter (mUhr/L)	Standard Deviation 142.547
Stage 1: PF-04856883 4 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	22.99 milliUnithour per liter (mUhr/L)	Standard Deviation 32.706
Stage 1: PF-04856883 8 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 4, 5, 6, 7, 5, 6)	39.96 milliUnithour per liter (mUhr/L)	Standard Deviation 38.941
Stage 1: PF-04856883 8 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	35.09 milliUnithour per liter (mUhr/L)	Standard Deviation 57.093
Stage 1: PF-04856883 8 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	210.80 milliUnithour per liter (mUhr/L)	Standard Deviation 95.536
Stage 1: PF-04856883 12 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 4, 5, 6, 7, 5, 6)	-50.51 milliUnithour per liter (mUhr/L)	Standard Deviation 40.624
Stage 1: PF-04856883 12 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	235.84 milliUnithour per liter (mUhr/L)	Standard Deviation 130.071
Stage 1: PF-04856883 12 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	12.15 milliUnithour per liter (mUhr/L)	Standard Deviation 54.495
Stage 1: PF-04856883 18 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	105.34 milliUnithour per liter (mUhr/L)	Standard Deviation 19.118
Stage 1: PF-04856883 18 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 4, 5, 6, 7, 5, 6)	38.04 milliUnithour per liter (mUhr/L)	Standard Deviation 15.736
Stage 1: PF-04856883 18 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	59.06 milliUnithour per liter (mUhr/L)	Standard Deviation 94.643
Stage 1: PF-04856883 24 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	257.73 milliUnithour per liter (mUhr/L)	Standard Deviation 127.358
Stage 1: PF-04856883 24 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	83.82 milliUnithour per liter (mUhr/L)	Standard Deviation 70.182
Stage 1: PF-04856883 24 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 4, 5, 6, 7, 5, 6)	-0.36 milliUnithour per liter (mUhr/L)	Standard Deviation 50.674
Stage 1: PF-04856883 36 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 4, 5, 6, 7, 5, 6)	1.08 milliUnithour per liter (mUhr/L)	Standard Deviation 47.135
Stage 1: PF-04856883 36 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	13.72 milliUnithour per liter (mUhr/L)	Standard Deviation 98.682
Stage 1: PF-04856883 36 mg	Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	283.59 milliUnithour per liter (mUhr/L)	Standard Deviation 156.831

Secondary

Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2

Change from baseline in post-prandial area under the plasma glucose concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.

Time frame: Baseline, Day 3, 15, 24, 29 and 50

Arm	Measure	Group	Value (MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline (n =7, 4, 7, 7, 6)	606.49 mg*hr/dL	Standard Deviation 158.249
Stage 1: PF-04856883 Placebo	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 29 (n =7, 4, 7, 6, 5)	30.08 mg*hr/dL	Standard Deviation 59.49
Stage 1: PF-04856883 Placebo	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 15 (n =7, 4, 6, 6, 6)	-18.48 mg*hr/dL	Standard Deviation 50.874
Stage 1: PF-04856883 Placebo	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 24 (n =7, 4, 7, 6, 5)	-6.20 mg*hr/dL	Standard Deviation 46.238
Stage 1: PF-04856883 Placebo	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 3 (n =7, 4, 5, 6, 5)	44.41 mg*hr/dL	Standard Deviation 74.405
Stage 1: PF-04856883 Placebo	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 50 (n =7, 3, 6, 6, 6)	50.26 mg*hr/dL	Standard Deviation 81.717
Stage 1: PF-04856883 4 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 24 (n =7, 4, 7, 6, 5)	-146.61 mg*hr/dL	Standard Deviation 78.863
Stage 1: PF-04856883 4 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 50 (n =7, 3, 6, 6, 6)	-48.82 mg*hr/dL	Standard Deviation 80.733
Stage 1: PF-04856883 4 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 3 (n =7, 4, 5, 6, 5)	-97.03 mg*hr/dL	Standard Deviation 55.692
Stage 1: PF-04856883 4 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline (n =7, 4, 7, 7, 6)	811.36 mg*hr/dL	Standard Deviation 131.145
Stage 1: PF-04856883 4 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 15 (n =7, 4, 6, 6, 6)	-265.64 mg*hr/dL	Standard Deviation 89.889
Stage 1: PF-04856883 4 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 29 (n =7, 4, 7, 6, 5)	-55.43 mg*hr/dL	Standard Deviation 74.973
Stage 1: PF-04856883 8 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 29 (n =7, 4, 7, 6, 5)	-157.54 mg*hr/dL	Standard Deviation 88.652
Stage 1: PF-04856883 8 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 3 (n =7, 4, 5, 6, 5)	-103.00 mg*hr/dL	Standard Deviation 118.759
Stage 1: PF-04856883 8 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 24 (n =7, 4, 7, 6, 5)	-207.12 mg*hr/dL	Standard Deviation 89.687
Stage 1: PF-04856883 8 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline (n =7, 4, 7, 7, 6)	756.17 mg*hr/dL	Standard Deviation 240.43
Stage 1: PF-04856883 8 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 50 (n =7, 3, 6, 6, 6)	-33.77 mg*hr/dL	Standard Deviation 250.859
Stage 1: PF-04856883 8 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 15 (n =7, 4, 6, 6, 6)	-293.04 mg*hr/dL	Standard Deviation 163.074
Stage 1: PF-04856883 12 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 50 (n =7, 3, 6, 6, 6)	-125.06 mg*hr/dL	Standard Deviation 217.403
Stage 1: PF-04856883 12 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 15 (n =7, 4, 6, 6, 6)	-254.54 mg*hr/dL	Standard Deviation 144.897
Stage 1: PF-04856883 12 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 24 (n =7, 4, 7, 6, 5)	-242.35 mg*hr/dL	Standard Deviation 231.302
Stage 1: PF-04856883 12 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 29 (n =7, 4, 7, 6, 5)	-192.97 mg*hr/dL	Standard Deviation 185.056
Stage 1: PF-04856883 12 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline (n =7, 4, 7, 7, 6)	800.66 mg*hr/dL	Standard Deviation 206.776
Stage 1: PF-04856883 12 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 3 (n =7, 4, 5, 6, 5)	-98.38 mg*hr/dL	Standard Deviation 114.644
Stage 1: PF-04856883 18 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 3 (n =7, 4, 5, 6, 5)	-68.52 mg*hr/dL	Standard Deviation 153.127
Stage 1: PF-04856883 18 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Baseline (n =7, 4, 7, 7, 6)	723.57 mg*hr/dL	Standard Deviation 220.872
Stage 1: PF-04856883 18 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 50 (n =7, 3, 6, 6, 6)	-23.99 mg*hr/dL	Standard Deviation 123.611
Stage 1: PF-04856883 18 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 29 (n =7, 4, 7, 6, 5)	-106.58 mg*hr/dL	Standard Deviation 171.297
Stage 1: PF-04856883 18 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 24 (n =7, 4, 7, 6, 5)	-121.13 mg*hr/dL	Standard Deviation 258.528
Stage 1: PF-04856883 18 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change at Day 15 (n =7, 4, 6, 6, 6)	-240.65 mg*hr/dL	Standard Deviation 252.349

Secondary

Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1

Change from baseline in post-prandial area under the plasma glucose concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC

Time frame: Baseline, Day 3 and 8

Arm	Measure	Group	Value (MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	7.72 milligramhour per deciliter (mghr/dL)	Standard Deviation 89.366
Stage 1: PF-04856883 Placebo	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 6)	-4.82 milligramhour per deciliter (mghr/dL)	Standard Deviation 75.396
Stage 1: PF-04856883 Placebo	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	656.35 milligramhour per deciliter (mghr/dL)	Standard Deviation 114.496
Stage 1: PF-04856883 4 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 6)	10.37 milligramhour per deciliter (mghr/dL)	Standard Deviation 158.368
Stage 1: PF-04856883 4 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	834.03 milligramhour per deciliter (mghr/dL)	Standard Deviation 158.952
Stage 1: PF-04856883 4 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	77.82 milligramhour per deciliter (mghr/dL)	Standard Deviation 125.011
Stage 1: PF-04856883 8 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	712.11 milligramhour per deciliter (mghr/dL)	Standard Deviation 88.942
Stage 1: PF-04856883 8 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	-89.38 milligramhour per deciliter (mghr/dL)	Standard Deviation 58.909
Stage 1: PF-04856883 8 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 6)	0.85 milligramhour per deciliter (mghr/dL)	Standard Deviation 125.384
Stage 1: PF-04856883 12 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 6)	-82.51 milligramhour per deciliter (mghr/dL)	Standard Deviation 48.898
Stage 1: PF-04856883 12 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	796.14 milligramhour per deciliter (mghr/dL)	Standard Deviation 208.733
Stage 1: PF-04856883 12 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	-101.47 milligramhour per deciliter (mghr/dL)	Standard Deviation 31.725
Stage 1: PF-04856883 18 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	660.64 milligramhour per deciliter (mghr/dL)	Standard Deviation 110.833
Stage 1: PF-04856883 18 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	-68.05 milligramhour per deciliter (mghr/dL)	Standard Deviation 111.431
Stage 1: PF-04856883 18 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 6)	-28.36 milligramhour per deciliter (mghr/dL)	Standard Deviation 61.456
Stage 1: PF-04856883 24 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	-141.27 milligramhour per deciliter (mghr/dL)	Standard Deviation 15.975
Stage 1: PF-04856883 24 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 6)	-123.43 milligramhour per deciliter (mghr/dL)	Standard Deviation 68.219
Stage 1: PF-04856883 24 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	652.20 milligramhour per deciliter (mghr/dL)	Standard Deviation 48.707
Stage 1: PF-04856883 36 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 8 (n =15, 5, 5, 6, 7, 5, 6)	-39.60 milligramhour per deciliter (mghr/dL)	Standard Deviation 85.256
Stage 1: PF-04856883 36 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Baseline (n =15, 5, 6, 6, 7, 5, 7)	636.57 milligramhour per deciliter (mghr/dL)	Standard Deviation 119.662
Stage 1: PF-04856883 36 mg	Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)	-153.04 milligramhour per deciliter (mghr/dL)	Standard Deviation 41.501

Secondary

Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 1

Time frame: predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1

Population: Pharmacokinetic (PK) parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 1	181.2 nanogram per milliliter (ng/mL)	Geometric Coefficient of Variation 85
Stage 1: PF-04856883 4 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 1	324.7 nanogram per milliliter (ng/mL)	Geometric Coefficient of Variation 61
Stage 1: PF-04856883 8 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 1	793.7 nanogram per milliliter (ng/mL)	Geometric Coefficient of Variation 65
Stage 1: PF-04856883 12 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 1	1855 nanogram per milliliter (ng/mL)	Geometric Coefficient of Variation 66
Stage 1: PF-04856883 18 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 1	1776 nanogram per milliliter (ng/mL)	Geometric Coefficient of Variation 21
Stage 1: PF-04856883 24 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 1	2006 nanogram per milliliter (ng/mL)	Geometric Coefficient of Variation 52

Secondary

Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 2

Time frame: predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336 hours postdose on Day 1; predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22

Population: PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, 'n' signifies those participants who were evaluable at specified time point for each arm, respectively.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 2	Day 1 (n =5, 7, 7, 6)	1369 ng/mL	Geometric Coefficient of Variation 17
Stage 1: PF-04856883 Placebo	Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 2	Day 22 (n =5, 7, 5, 6)	1802 ng/mL	Geometric Coefficient of Variation 33
Stage 1: PF-04856883 4 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 2	Day 22 (n =5, 7, 5, 6)	2757 ng/mL	Geometric Coefficient of Variation 26
Stage 1: PF-04856883 4 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 2	Day 1 (n =5, 7, 7, 6)	1203 ng/mL	Geometric Coefficient of Variation 20
Stage 1: PF-04856883 8 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 2	Day 1 (n =5, 7, 7, 6)	1027 ng/mL	Geometric Coefficient of Variation 29
Stage 1: PF-04856883 8 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 2	Day 22 (n =5, 7, 5, 6)	3030 ng/mL	Geometric Coefficient of Variation 42
Stage 1: PF-04856883 12 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 2	Day 1 (n =5, 7, 7, 6)	1407 ng/mL	Geometric Coefficient of Variation 29
Stage 1: PF-04856883 12 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 2	Day 22 (n =5, 7, 5, 6)	3046 ng/mL	Geometric Coefficient of Variation 24

Secondary

Number of Participants With Anti-Drug Antibodies (ADA): Stage 1

Time frame: Day 1 and 29

Population: Safety population included all participants who received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable at specified time point for each arm, respectively.

Arm	Measure	Group	Value (NUMBER)
Stage 1: PF-04856883 Placebo	Number of Participants With Anti-Drug Antibodies (ADA): Stage 1	Day 1 (n =5, 6, 6, 7, 5, 7)	1 participants
Stage 1: PF-04856883 Placebo	Number of Participants With Anti-Drug Antibodies (ADA): Stage 1	Day 29 (n =5, 5, 6, 6, 5, 7)	1 participants
Stage 1: PF-04856883 4 mg	Number of Participants With Anti-Drug Antibodies (ADA): Stage 1	Day 1 (n =5, 6, 6, 7, 5, 7)	1 participants
Stage 1: PF-04856883 4 mg	Number of Participants With Anti-Drug Antibodies (ADA): Stage 1	Day 29 (n =5, 5, 6, 6, 5, 7)	2 participants
Stage 1: PF-04856883 8 mg	Number of Participants With Anti-Drug Antibodies (ADA): Stage 1	Day 1 (n =5, 6, 6, 7, 5, 7)	0 participants
Stage 1: PF-04856883 8 mg	Number of Participants With Anti-Drug Antibodies (ADA): Stage 1	Day 29 (n =5, 5, 6, 6, 5, 7)	1 participants
Stage 1: PF-04856883 12 mg	Number of Participants With Anti-Drug Antibodies (ADA): Stage 1	Day 1 (n =5, 6, 6, 7, 5, 7)	0 participants
Stage 1: PF-04856883 12 mg	Number of Participants With Anti-Drug Antibodies (ADA): Stage 1	Day 29 (n =5, 5, 6, 6, 5, 7)	0 participants
Stage 1: PF-04856883 18 mg	Number of Participants With Anti-Drug Antibodies (ADA): Stage 1	Day 1 (n =5, 6, 6, 7, 5, 7)	0 participants
Stage 1: PF-04856883 18 mg	Number of Participants With Anti-Drug Antibodies (ADA): Stage 1	Day 29 (n =5, 5, 6, 6, 5, 7)	0 participants
Stage 1: PF-04856883 24 mg	Number of Participants With Anti-Drug Antibodies (ADA): Stage 1	Day 1 (n =5, 6, 6, 7, 5, 7)	2 participants
Stage 1: PF-04856883 24 mg	Number of Participants With Anti-Drug Antibodies (ADA): Stage 1	Day 29 (n =5, 5, 6, 6, 5, 7)	2 participants

Secondary

Number of Participant With Anti-Drug Antibodies (ADA): Stage 2

Time frame: Day 1, 29 and 50

Arm	Measure	Group	Value (NUMBER)
Stage 1: PF-04856883 Placebo	Number of Participant With Anti-Drug Antibodies (ADA): Stage 2	Day 1 (n =5, 7, 7, 6)	0 participants
Stage 1: PF-04856883 Placebo	Number of Participant With Anti-Drug Antibodies (ADA): Stage 2	Day 50 (n =5, 7, 6, 6)	0 participants
Stage 1: PF-04856883 Placebo	Number of Participant With Anti-Drug Antibodies (ADA): Stage 2	Day 29 (n =5, 7, 6, 5)	0 participants
Stage 1: PF-04856883 4 mg	Number of Participant With Anti-Drug Antibodies (ADA): Stage 2	Day 1 (n =5, 7, 7, 6)	1 participants
Stage 1: PF-04856883 4 mg	Number of Participant With Anti-Drug Antibodies (ADA): Stage 2	Day 29 (n =5, 7, 6, 5)	2 participants
Stage 1: PF-04856883 4 mg	Number of Participant With Anti-Drug Antibodies (ADA): Stage 2	Day 50 (n =5, 7, 6, 6)	3 participants
Stage 1: PF-04856883 8 mg	Number of Participant With Anti-Drug Antibodies (ADA): Stage 2	Day 29 (n =5, 7, 6, 5)	2 participants
Stage 1: PF-04856883 8 mg	Number of Participant With Anti-Drug Antibodies (ADA): Stage 2	Day 1 (n =5, 7, 7, 6)	1 participants
Stage 1: PF-04856883 8 mg	Number of Participant With Anti-Drug Antibodies (ADA): Stage 2	Day 50 (n =5, 7, 6, 6)	2 participants
Stage 1: PF-04856883 12 mg	Number of Participant With Anti-Drug Antibodies (ADA): Stage 2	Day 50 (n =5, 7, 6, 6)	3 participants
Stage 1: PF-04856883 12 mg	Number of Participant With Anti-Drug Antibodies (ADA): Stage 2	Day 1 (n =5, 7, 7, 6)	0 participants
Stage 1: PF-04856883 12 mg	Number of Participant With Anti-Drug Antibodies (ADA): Stage 2	Day 29 (n =5, 7, 6, 5)	1 participants

Secondary

Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2

HbA1c is a measure of the glycosylated hemoglobin. Change (measured as percent): HbA1c at observation minus HbA1c at baseline. Outcome measure was planned to analyzed only for Stage 2.

Time frame: Baseline, Day 29 and 50

Arm	Measure	Group	Value (MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2	Day 50 (n =6, 5, 7, 7, 6)	0.15 percent	Standard Deviation 0.769
Stage 1: PF-04856883 Placebo	Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2	Day 29 (n =7, 5, 7, 6, 5)	0.06 percent	Standard Deviation 0.547
Stage 1: PF-04856883 4 mg	Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2	Day 50 (n =6, 5, 7, 7, 6)	-0.08 percent	Standard Deviation 0.335
Stage 1: PF-04856883 4 mg	Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2	Day 29 (n =7, 5, 7, 6, 5)	-0.24 percent	Standard Deviation 0.288
Stage 1: PF-04856883 8 mg	Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2	Day 50 (n =6, 5, 7, 7, 6)	-0.24 percent	Standard Deviation 0.326
Stage 1: PF-04856883 8 mg	Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2	Day 29 (n =7, 5, 7, 6, 5)	-0.41 percent	Standard Deviation 0.212
Stage 1: PF-04856883 12 mg	Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2	Day 29 (n =7, 5, 7, 6, 5)	-0.42 percent	Standard Deviation 0.44
Stage 1: PF-04856883 12 mg	Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2	Day 50 (n =6, 5, 7, 7, 6)	-0.33 percent	Standard Deviation 0.754
Stage 1: PF-04856883 18 mg	Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2	Day 29 (n =7, 5, 7, 6, 5)	-0.40 percent	Standard Deviation 0.43
Stage 1: PF-04856883 18 mg	Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2	Day 50 (n =6, 5, 7, 7, 6)	-0.40 percent	Standard Deviation 0.58

Secondary

Terminal Elimination Half- Life (t1/2) of PF-04856883: Stage 1

Time frame: predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1

Arm	Measure	Value (MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Terminal Elimination Half- Life (t1/2) of PF-04856883: Stage 1	146.3 hour	Standard Deviation 13.614
Stage 1: PF-04856883 4 mg	Terminal Elimination Half- Life (t1/2) of PF-04856883: Stage 1	179.7 hour	Standard Deviation 14.572
Stage 1: PF-04856883 8 mg	Terminal Elimination Half- Life (t1/2) of PF-04856883: Stage 1	147.0 hour	Standard Deviation 18.52
Stage 1: PF-04856883 12 mg	Terminal Elimination Half- Life (t1/2) of PF-04856883: Stage 1	133.8 hour	Standard Deviation 23.936
Stage 1: PF-04856883 18 mg	Terminal Elimination Half- Life (t1/2) of PF-04856883: Stage 1	173.7 hour	Standard Deviation 7.0238
Stage 1: PF-04856883 24 mg	Terminal Elimination Half- Life (t1/2) of PF-04856883: Stage 1	131.6 hour	Standard Deviation 45.883

Secondary

Terminal Elimination Half-life (t1/2) of PF-04856883: Stage 2

Time frame: predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22

Arm	Measure	Value (MEAN)	Dispersion
Stage 1: PF-04856883 Placebo	Terminal Elimination Half-life (t1/2) of PF-04856883: Stage 2	149.4 hour	Standard Deviation 21.87
Stage 1: PF-04856883 4 mg	Terminal Elimination Half-life (t1/2) of PF-04856883: Stage 2	135.0 hour	Standard Deviation 43.98
Stage 1: PF-04856883 8 mg	Terminal Elimination Half-life (t1/2) of PF-04856883: Stage 2	143.8 hour	Standard Deviation 20.565
Stage 1: PF-04856883 12 mg	Terminal Elimination Half-life (t1/2) of PF-04856883: Stage 2	145.0 hour	Standard Deviation 37

Secondary

Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 1

Time frame: predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1

Population: PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest.

Arm	Measure	Value (MEDIAN)
Stage 1: PF-04856883 Placebo	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 1	168 hour
Stage 1: PF-04856883 4 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 1	120 hour
Stage 1: PF-04856883 8 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 1	120 hour
Stage 1: PF-04856883 12 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 1	120 hour
Stage 1: PF-04856883 18 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 1	120 hour
Stage 1: PF-04856883 24 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 1	122 hour

Secondary

Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 2

Time frame: predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336 hours postdose on Day 1; predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22

Population: PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, 'n' signifies those participants who were evaluable at specified time point for each arm, respectively.

Arm	Measure	Group	Value (MEDIAN)
Stage 1: PF-04856883 Placebo	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 2	Day 1 (n =5, 7, 7, 6)	336 hour
Stage 1: PF-04856883 Placebo	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 2	Day 22 (n =5, 7, 5, 6)	48.0 hour
Stage 1: PF-04856883 4 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 2	Day 22 (n =5, 7, 5, 6)	72.0 hour
Stage 1: PF-04856883 4 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 2	Day 1 (n =5, 7, 7, 6)	336 hour
Stage 1: PF-04856883 8 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 2	Day 1 (n =5, 7, 7, 6)	335 hour
Stage 1: PF-04856883 8 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 2	Day 22 (n =5, 7, 5, 6)	72.0 hour
Stage 1: PF-04856883 12 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 2	Day 1 (n =5, 7, 7, 6)	336 hour
Stage 1: PF-04856883 12 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 2	Day 22 (n =5, 7, 5, 6)	60.0 hour

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements

Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)

Number of Participants With Clinically Significant Physical Examination Findings

Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

Number of Participants With Vital Sign Abnormalities

Apparent Clearance (CL/F) of PF-04856883: Stage 1

Apparent Clearance (CL/F) of PF-04856883: Stage 2

Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 1

Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 2

Area Under the Concentration Time Curve From Time Zero to Time Tau (AUCtau) of PF-04856883: Stage 2

Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) of PF-04856883: Stage 1

Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2

Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1

Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2

Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2

Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1

Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1

Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2

Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2

Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1

Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2

Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1

Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2

Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1

Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 1

Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 2

Number of Participants With Anti-Drug Antibodies (ADA): Stage 1

Number of Participant With Anti-Drug Antibodies (ADA): Stage 2

Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2

Terminal Elimination Half- Life (t1/2) of PF-04856883: Stage 1

Terminal Elimination Half-life (t1/2) of PF-04856883: Stage 2

Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 1

Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 2